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Abstract
Introduction: The contributions of transplant pharmacists to clinical and translational
research in the United States are ill-defined and have not been systematically reviewed.
Objectives: The American College of Clinical Pharmacy Immunology/Transplantation
Practice and Research Network conducted a systematic review of available pharmacist-
led research publications involving solid organ transplantation with the intent to quantify
and describe pharmacist-led research endeavors and their changes over time.
Methods: An electronic search of Scopus was conducted to identify publications in
the field of solid organ transplantation by pharmacist authors between January
1, 1975 and May 25, 2017. Articles were excluded if they were written in non-
English languages or originated from non-US countries. Review articles, case reports,
surveys, basic science research, pre-clinical studies, and non-transplant research were
further excluded. Studies were categorized as one of four phases on the clinical and
translational research spectrum, adapted from the Harvard Clinical and Translational
Science Center description of a T1 to T4 classification system.
Results: A total of 10 354 publications were identified by the systematic search with
547 full-text English-language publications included in the analysis. Pharmacists
served as the first author in 87% of the articles and as the senior author in 67% of
the articles. A total of 71% of the articles included more than one pharmacist author.
Transplant pharmacists published more studies that employed a retrospective or
observational study design (55% and 78%, respectively). A total of 37% of studies
were funded. On the spectrum of clinical and translation research, pharmacists were
most involved in T3 (translation to practice) research (72%), followed by T2 (transla-
tion to patients) research (23%).
This paper represents the opinion of the Immunology/Transplantation Practice and Research Network of the American College of Clinical Pharmacy. It does not necessarily represent an official
ACCP commentary, guideline, or statement of policy or position.
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Conclusions: Transplant pharmacists are increasingly represented in the US literature
and frequently published across domains. Further demonstrating the relevance of
pharmacist-delivered interventions and outcomes is a critical area of practice focus.
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INTRODUCTION
The role of pharmacists on the multidisciplinary transplant team has
been well recognized; however, their role and involvement in clinical
and translational research is less well defined.1-3 The transplant
environment changed drastically in the United States in 2007 with the
Centers for Medicare and Medicaid Services (CMS) Conditions of
Participation outlining requirements for quality assurance perfor-
mance improvement (QAPI) programs to be established at each trans-
plant center.4 While an increasing number of transplant pharmacists
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serve as directors of clinical research or quality for transplant centers,
many transplant pharmacists with primary clinical responsibilities are
actively engaged in the development of clinical and research proto-
cols, evaluation of clinical outcomes, navigation/implementation of
industry-sponsored or supported trials, and regulatory and reporting
efforts.1,3 As transplant pharmacists report being tasked with higher-
level clinical and translational research and/or QAPI responsibilities,
the inability to assign a monetary value to the positive impact of
transplant pharmacists as team members and obtain reimbursement
has been suggested as a barrier to building the business case for the
value of pharmacist-provided services.2 While it is evident that trans-
plant pharmacists are playing substantial roles within transplant
research and QAPI, these contributions have not been systematically
reviewed.
The American College of Clinical Pharmacy (ACCP) Immunol-
ogy/Transplantation Practice Research Network (PRN) conducted a
systematic review of available pharmacist-led research publications
involving solid organ transplantation with the intent to quantify
pharmacist-led research endeavors and describe changes over time.
This review not only summarizes the types of research studies that
transplant pharmacists have led, including study design, population,
type of research, and funding, but also discusses the gaps in the
current literature to aid in targeting future research and scholarly
efforts.
METHODS
A protocol for the literature search, screening, and review strategy
was developed with input from content experts and experts trained in
performing systematic reviews. The protocol was designed with our
primary purpose in mind: conducting a systematic review of available
pharmacist-led research publications involving solid organ transplanta-
tion with the intent to quantify and describe pharmacist-led research
endeavors and their changes over time.
Data sources and searches
On May 25, 2017, an electronic search of Scopus was conducted to
identify publications in the field of solid organ transplantation by
pharmacist authors. In the Scopus database, the following combina-
tions of search terms were used: (TITLE-ABS-KEY [“liver transplant*”
OR “liver-kidney transplant*” OR “lung transplant*” OR “pancreas
transplant*” OR “organ transplant*” OR “heart transplant*” OR “heart-
lung transplant*” OR “kidney transplant*” OR “kidney-pancreas trans-
plant*” OR “intestin* transplant*” OR “multivisceral transplant*”] AND
AFFIL[pharmacy]). In addition, historical membership lists from the
ACCP Immunology/Transplantation PRN, the American Society of
Transplantation Community of Practice (AST CoP) of Transplant Phar-
macists, and the International Society of Heart and Lung Transplant
(ISHLT) Pharmacy Council were obtained and each pharmacist was
searched individually by last name and first initial, excluding manu-
scripts with AFFIL (pharmacy), so as to include pharmacists without an
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Notes: T1, translation to humans; T2, translation to patients; T3, transla-
tion to practice; T4, translation to population health.
TABLE 2 Pharmacist authorship by position and publication era
Variables (N = 547) N (%)
Authorship position, n (%)
Pharmacist first author 475 (86.8)
Pharmacist senior author 365 (66.7)
Multiple pharmacists on publication 398 (70.6)









2016-May 25, 2017 19 (34.7)
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affiliation to a department or college of pharmacy. The same search
was performed using PubMed, which did not extract any further
results.
Eligibility criteria and screening
We included biomedical or health science research articles with one
or more pharmacist lead authors (defined as first author, last author,
or both) from the publication year 1975 onwards. Articles were
excluded if they were written in non-English languages or originated
from non-US countries. Review articles, case reports, surveys, basic
science research, pre-clinical studies, and non-transplant research
were further excluded (Figure 1). Screening was conducted by one
pair of researchers against the inclusion and exclusion criteria. Dis-
agreements regarding inclusion were resolved via discussion within
the pair. Referencing software was used to manage included and
excluded publications and remove duplicate search results.
Publication content assessment
Based on the review aims, a content assessment tool was developed,
reviewed, and approved by the research team (Table 1). Our main
interest was describing transplant pharmacist-led clinical and transla-
tional research according to the following categories: study design,
study type, study population, center/country involvement, funding
source, T-phases of research spectrum, subject domain, and
pharmacist-delivered intervention. Author's affiliations to center/
country and funding source were identified from the publication.
Studies were categorized as one of four phases on the clinical and
translational research spectrum, adapted from the Harvard Clinical
and Translational Science Center description of T1 to T4 classification
system (Appendix, Table A1).5 This system classifies studies based
on how the study results translate (eg, T1—Translation to humans;
T2—Translation to patients; T3—Translation to practice; T4—Translation
to population health). While it incorporates the drug development
classifiers (Phases I-IV), it is not limited to drug-development and
encompasses all types of research. Based on the primary objective,
studies were categorized into one of the following four subject
domains: pharmacology (eg, drug formulation, pharmacokinetics,
pharmacodynamics, pharmacogenomics, dosing), clinical outcomes
(eg, rejection, infection, metabolic complications, surgical complica-
tions, medication-related problems/adverse drug events), patient-
reported and behavioral outcomes (eg, education, adherence, quality
of life, satisfaction, patient-reported health care burden), and public
health (eg, epidemiology, pharmacoeconomics).
The full-text documents of eligible publications were retrieved.
Content assessment was delegated to pairs of researchers for inde-
pendent review. Each article was reviewed by a first reviewer and
then independently verified by a second reviewer. Disagreements
regarding content category were resolved via discussion and, in the
event that there was not resolution to this disagreement, it was esca-
lated to an independent party for final determination.
RESULTS
A total of 10 354 publications were identified through the systematic
search between January 1, 1975 and May 25, 2017. After applying
the inclusion and exclusion criteria, 547 full-text English-language
publications with pharmacist lead or senior authors were identified
and included in the content review (Figure 1). Pharmacists served as
the first author in 86.8% of the articles and as the senior author in
66.7% of the articles. Approximately 70% of the articles included
more than one pharmacist author (Table 2). The number of
F IGURE 2 Pharmacist-led publications over time (1975-2015). This figure depicts the number of publications for each 5-year era where a
pharmacist is the first author (far left bar chart), the last (senior) author (middle bar chart), or where pharmacists were in both the first and last
author position (far right bar chart). The star in the 2001 to 2005 era indicates that it is the era in which the United Network for Organ Sharing
bylaws changed to identify pharmacists as an integral member of the multidisciplinary team
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pharmacist-led clinical and translational research publications in the
field of solid organ transplantation has increased drastically since
2004, reaching over 200 publications per decade in the recent era
(Table 2). The increase of pharmacist authorship was observed in
both first and senior authorship (Figure 2). It was common (90% of
the time) for pharmacists from a single institution to work together,
however, pharmacists also collaborated with researchers from
other institutions within the United States or at the international level.
The study design most frequently utilized was retrospective or
observational, (54.5% and 77.8%, respectively). The study population
predominantly included adults that received abdominal organ trans-
plantation. Nearly, 40% of the published studies were funded by
industry or local/national public entities (Table 3).
On the spectrum of clinical and translation research, pharmacists
were most involved in T3 research (72.2%), followed by T2 research
(22.8%). Only about 5% of the pharmacist-led publications were in T1
and T4 research categories (Table 3). Pharmacists published mostly in
the research domains of clinical outcomes and pharmacology,
followed by public health domain. Pharmacist involvement in patient-
reported and behavioral outcomes research was less frequent in com-
parison to other subject areas (Figure 3). Of the 547 publications
reviewed, only 10 papers (1.8%) focused on pharmacist-delivered
interventions and their outcomes (Table 4).6-15
DISCUSSION
To the best of our knowledge, this is the first paper to systematically
evaluate pharmacist-led research in a specialty practice. Transplant
pharmacists have clearly demonstrated significant contributions to
the literature as well as a transition from bench research to clinical
research. The transplant pharmacists' research repository spans
patient safety and allograft outcomes, impact on medication cost sav-
ings, and defining value in solid organ transplantation through
improved health care utilization. In 2004, the United Network for
TABLE 3 Publication details












Simultaneous pancreas/kidney 14 (2.6)
Combined liver/kidney 0 (0)
Heart 37 (6.7)
Lung 46 (8.4)
Small bowel 1 (0.2)
Combined (multiple transplant populations included) 68 (12.4)
Healthy volunteers 10 (1.8)
Study population by age
Adult 475 (86.8)
Pediatric 31 (5.7)
Non-age specific 41 (7.5)
Center involvement
Single center 478 (87.4)
Multi-center 50 (9.1)
National database 19 (3.4)
Country involvement





Other non-profit 20 (3.6)
Industry 73 (13.3)
T-phase of research spectrum
T1: Translation to humans 10 (1.8)
T2: Translation to patients 125 (22.8)
T3: Translation to practice 395 (72.2)
T4: Translation to population health 17 (3.1)
F IGURE 3 Pharmacist-led
publications by subject domain
(1975-2015). This figure depicts
the number of publications by
pharmacists during each 5-year
era divided into research subject
domain
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TABLE 4 Research Publications on Pharmacist-Delivered Interventions
Reference Study design Setting Study population Pharmacist interventions Outcomes
Byrns et al6 Retrospective cohort
(n = 97)
Single center Kidney and kidney/
pancreas
Enrollment in a patient-assistance
program (PAP) for CMV
prophylaxis vs Pre-emptive
monitoring for patients who
cannot afford CMV prophylaxis
CMV viremia was lower in the
PAP group (12.8% vs 36.2%,
P = .021) at 1 year
Chisholm et al 7 Prospective,
randomized trial
(n = 24)
Single center Kidney transplant
recipients
The intervention group received
clinical pharmacy services in
addition to routine clinic services,
while the control group received
no pharmacist interaction
The compliance rate for patients
seen by clinical pharmacists was
higher than those receiving
standard care (96.1 ± 4.7% vs
81.6 ± 11.5%, P < .001); at
12 months, 75% of intervention
patients remined compliant vs
33.3% of control (P < .05); levels
in the intervention group
achieved 64% of the time vs
48% in control group (P < .05)
Chisholm et al8 Prospective,
randomized trial
(n = 23)
Single center African American
kidney transplant
patients
The intervention group received
clinical pharmacy services in
addition to routine clinic services,
while the control group received
no pharmacist interaction
Mean SBP was significantly lower
in the intervention group at the
second (137.8 ± 15.0 vs 168.9 ±
15.3), third (135.9 ± 11.7 vs
164.6 ± 20.1), and fourth
(145.3 ± 16.8 vs 175.8 ± 33.9)
quarters of the study (P < .05).
Mean DBP was significantly
lower in the intervention group
at the second (76.0 ± 11.8 vs
84.9 ± 6.1) and fourth (77.0 ±
10.2 vs 91.8 ± 12.0) quarters
(P < .05)
Chisholm et al9 Retrospective
analysis (n = 36)
Single center Kidney transplant
recipients
Renal transplant recipients who
were enrolled in the Medication
Access Program (MAP) for at least
1 year and had diagnoses of
hypertension, diabetes, and
dyslipidemia. Control of chronic
conditions were compared from
pre- to post-enrollment
Patients enrolled in the MAP has
more medication prescribed for
control of diabetes,
hypertension, and dyslipidemia.
The patients saw a significant
improvement in fasting blood
glucose, HbA1c, LDL, total
cholesterol, triglycerides, blood
pressure, serum calcineurin
inhibitor levels, and rejection
rates, as well as health-related
quality of life scores
Migliozzi et al10 Retrospective
analysis (n = 50)
Single center Kidney transplant
recipients
Patients were enrolled in a




Their BP from 1 year prior to
enrollment were compared with
BP in the year after enrollment
Patients' mean SBP and DBP
values were significantly lower
at 30, 90, 180, and 360 days
after program enrollment
(P < .05)
Pinelli et al11 Retrospective
analysis (n = 22)







Patients who were enrolled in the
PMDC had their clinical outcomes
compared between baseline and 3
and 6 months after entry into the
clinic
Patients with a baseline
HbA1c > 7.5% had a significant
reduction by the end of follow-
up (8.1 ± 1.0% vs 7.3 ± 1.2% at
3 months and 7.5 ± 0.8% at
6 months); 30- and 90-day
readmission rates significantly
decreased (18.1% vs 29.5% and
31.8% vs 38.9%, respectively),
yet were similar at 180 days
(Continues)
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Organ Sharing (UNOS) and the CMS formally recognized transplant
pharmacists as an integral member of the multidisciplinary care team.4
Our data revealed that with the advent of these additional regulations
within solid organ transplantation practice in the United States, there
was a resultant impact on the number of publications led by transplant
pharmacists (Figures 2 and 3). As additional QAPI activities were
required in solid organ transplantation in 2007, it was natural for the
transplant pharmacist to become more involved in QAPI activities and
related research.4 It appears that there was an additional increase in
transplant pharmacist-led publications by 2011 to 2015.1
The health care payment model in the United States is shifting
from fee-for-service to value-based care with a focus on quality, out-
comes, and cost. As one of the most accessible health care team mem-
bers, this transformation has provided increasing opportunities to
integrate pharmacists into a team-based approach to further optimize
patient care. As a function of their basic daily activities, transplant
TABLE 4 (Continued)
Reference Study design Setting Study population Pharmacist interventions Outcomes
Staino et al12 Retrospective cross-
sectional analysis
(n = 219)
Single center Kidney transplant
recipients
During a 3-month period,
pharmacist in-person clinic visits
(n = 175) were compared with
pharmacist chart review and
recommendation documentation
(n = 170)
Providers accepted a greater
percentage of recommendations
that were delivered directly
compared with
recommendations presented via
a note in the patient folder
following chart review (92% vs
28%, respectively; P < .0001)
Taber et al13 Retrospective
analysis
Single center Kidney transplant
recipients
Follow-up analysis of a pharmacist-
led team that developed key
initiatives including improved
medication reconciliation,






by >2 per patient; pharmacist-
reviewed discharge medications
reduced medication safety
issues by 40%; delayed
discharges reduced by 14%;
7-day readmission rates
reduced by 50%
Taber et al14 Retrospective
analysis of
outcomes of single
center (n = 583)
compared with
national database
(n = 37 712)
Single center Kidney transplant
recipients
Follow-up analysis of a pharmacist-
led team that developed key
initiatives including improved
medication reconciliation,





Quality initiatives reduced length
of stay in patients with delayed-
graft function from 8 days to
4 days; overall LOS was
reduced from 3.6 ± 1.5 to 3.3
± 0.8 days, P = .021, as
compared with a national LOS
of 10 days; hospital costs
reduced by 42%, while national
costs increased by 12%;
institutional 30-day readmission
rates better than national in all
patients and DGF patients (9%








Single center Kidney transplant
recipients at least
21 years old, at








least 1 year prior to
study enrollment
Subjects randomized into the
intervention group received a
negotiated immunosuppression
adherence contract and meetings
at 3-, 6-, and 9-months to review
the contract and discuss progress
The intervention group (n = 76)
had higher adherence than the
control group (n = 74) (P < .01).
There were more patients that
avoided hospitalization in the
intervention vs the control (76.1
vs 42.7%, RR = 1.785, 95% CI
1314,2.425)
Abbreviations: BP, blood pressure; CMV, cytomegalovirus; DBP, diastolic blood pressure; DGF, delayed graft function; HbA1c, glycosylated hemoglobin;
LDL, low-density lipoprotein; LOS, length of stay; SBP, systolic blood pressure.
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pharmacists provide critical medication therapy expertise and impor-
tant medication adjustments, either independently or with mutual
agreement from the prescriber, but without insurer reimbursement
for effort. Some early state adopters, such as the state of Washington,
have allowed pharmacists to practice under collaborative drug therapy
agreements. It was not until 2015, however, that additional recogni-
tion enabled billing from major insurance carriers.16
Transplant pharmacists have had a substantial impact on advanc-
ing knowledge through publication, as demonstrated in this systematic
review. For this reason, we urge transplant pharmacists to continue to
publish their work, specifically as it relates to patient outcomes
(phases T2-T4). It is difficult in today's health care environment to
substantiate and incur additional salary costs, so it is imperative to
continue to demonstrate through objective measures the impact of
the transplant pharmacist. These publications will lay the groundwork
for justification of additional transplant pharmacist positions within
both clinical and academic entities. Considering the profession of
pharmacy at large, we need to continue to strive to demonstrate posi-
tive impact in our quest to establish provider status.16-18 It would be
hard to imagine a better catalyst for this goal than for various special-
ties to increase their contribution to the literature and demonstrate
their impact on patient outcomes and health care value.
Our manuscript does have some limitations. Because of the amount
of time required to review and process the manuscripts, there was a
delay in our analysis that inherently fails to describe manuscripts publi-
shed after the initial Scopus search. Our analysis also did not include
research publications co-authored by transplant pharmacists if they were
not one of the lead authors. We hope that this can lay a foundation for
future updates and refinements. It also would have been ideal to com-
pare manuscripts led by transplant pharmacists with the total number of
publications related to transplant published during the same time frame.
In order to accurately define this total, considering the criteria applied to
the target publications would have been a huge undertaking and led to a
significant delay in publication. We feel, however, that this paper can
serve as a framework for similar assessment by other pharmacy special-
ties. In addition, we provide references and descriptions of the clinical
outcome manuscripts that describe and analyze pharmacist actions as
the intervention to lay a groundwork for demonstrating the impact of
the transplant pharmacist. This, in conjunction with other publications
illustrating the transplant pharmacist role, should provide the beginning
of a blue-print for identifying published data that supports an increase in
transplant pharmacist positions, as well as the role of the pharmacist as
an independent provider.1-3,18-21 Because of the limited number of these
studies, it is imperative that transplant pharmacists identify and publish
pharmacist-based intervention research within solid organ transplanta-
tion to better justify transplant pharmacist roles in the clinical, research,
and quality arenas.
CONCLUSION
A change in transplant regulation as well as a clearer definition of the
role of the transplant pharmacist has led to significant growth in
publications with a pharmacist as a primary or senior author. Our sys-
tematic review demonstrated that transplant pharmacists have
increased their representation in the literature and frequently publish
across domains. This paper, which has outlined the breadth and
impact of transplant pharmacy publications, may serve as an example
to other pharmacy specialties interested in creating a repository of
their own. As roles and services have expanded, we have identified
pharmacist-delivered interventions and outcomes as an area of critical
need for future growth in publications. Professional organizations may
aid in this endeavor by developing or maintaining support for investi-
gators in clinical research, with a specific focus on research designed
to highlight the impact of the transplant pharmacist in patient care.
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APPENDIX
TABLE A1 T-phases of clinical and translational research spectrum
Research type Definition Examples
T0—basic research goal: understand the
human condition and environment as it
exists
• Fundamental mechanisms of
biology, disease or behavior
• No immediately practical
application
• Benchwork including:
 Chemicals, molecules, devices,
structures
 Biomarkers, cells, proteins, DNA,
tissues, chemistries
 Radiology, biopsy
 Natural histories, observations,
patterns, classifications, correlations
 Gene mapping, banking, sequencing
T0—Pre-clinical research
Goal: understand the human condition and
environment as it exists
• Connection between the basic
science of disease with human
medicine
• Interventions developed to
further understand the basis of a
disease or disorder
• **KEY—Testing carried out using
 Cell or animal models of
disease
 Samples of human or animal
tissues
 Computer-assisted
simulations of drug, device, or
diagnostic interactions with
living systems
• Preclinical studies including:
 Chemicals, molecules, devices,
structures
 Biomarkers, cells, proteins, DNA,
tissues, chemistries
 Radiology, biopsy
 Natural histories, observations,
patterns, classifications, correlations
 Gene mapping, banking, sequencing
Clinical/translational research
T1-Translation to humans
Discovery to candidate health application
Goal: identify and analyze the effects of an
intervention or relationship on the human
condition or environment
• Application of preclinical studies
to humans
• First in humans (typically in
healthy volunteers)
• Proof of concept
• T1 research expedites the
movement from basic research to
patient-oriented research
(findings from basic research are
tested for clinical effect and/or




• Phase I clinical trials
 Proof of concept
 Health subjects or select population
of patients
 Small sample size
 Tests for safety
• Observational studies, for example,
association of BRCA mutations and
breast cancer; association between
CYP3A5 genotype and tacrolimus PK in
healthy volunteers
T2-Translation to Patients
Health application to evidence-based
practice guidelines
Goal: identify and analyze the optimal
effects of an intervention or relationship
on the human condition or environment
• Investigators test new
interventions under controlled
environments to form the basis
for clinical application and
evidence-based guidelines
• T2 research yields knowledge
about the efficacy of the
interventions in optimal settings
• Phases II and III clinical trials
 Select population of patients
 Larger sample size
• Evidence synthesis and guideline
development (eg, a randomized controlled
trial of CYP3A5 genotype-guided
tacrolimus dosing in transplant patients;
CPIC guideline for tacrolimus andCYP3A5)
• Observational studies
(eg, predictive value of BRCA mutations
in at-risk women; association between
CYP3A5 genotype and tacrolimus




(eg, economic analysis of a clinical trial)
(Continues)
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Research type Definition Examples
T3-Translation to Practice
Practice guidelines to health practice
Goal: incorporate into practice the optimal
intervention or relationship
• Investigators explore ways of
applying recommendations or
guidelines in general practice
• T3 research yields knowledge
about how interventions work in
real-world settings
• Studies which examine use,
costs, quality, accessibility,
delivery, organization, financing,
and outcomes of health care
services to increase knowledge
and understanding of the
structure, processes, and effects
of health services
• Phase IV clinical trials
(eg, impact of CYP3A5 genotype-guided
tacrolimus dosing per the CPIC guideline
on patient outcomes and costs in a
single-center kidney transplant program)




• Clinical outcomes research
• Observational studies
(eg, comparing clinical and cost
outcomes of a new practice/process
[e.g., immunosuppression protocol,




T4-Translation to Population Health
Practice to population health impact
Goal: provide communities with the optimal
intervention or relationship
• Investigators study factors and
interventions that influence the
health of populations. T4
research ultimately results in
improved global health
• Population-level outcome studies
• Population monitoring of morbidity,
mortality, benefits and risks
• Social determinants of health
• Population-based prevention and
outcome studies
• Investigating outcomes of mass
screening
• Comparative study of various health
policies and their impact on health and
health care utilization
• Social determinants of health
• Cost effectiveness/comparative
effectiveness
Abbreviations: CPIC, Clinical Pharmacogenetics Implementation Consortium; CYP, Cytochrome P450; PK, pharmacokinetics.
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